KalVista's Oral HAE Treatment Delivers 76-Minute Relief as FDA Review Nears - Stock Titan
2025-03-12 • Google News
Kalvista Pharmaceuticals Inc (KALV)
US$ 11.412.06%
Price Chart
Key Statistics
Market Cap
$ 605.54M
P/E Ratio
0.00
Revenue (TTM)
$ 3.82M
Volume
339.03K
52W High
$ 15.50
52W Low
$ 7.30
Dividend Yield
0.00%
Beta
0.05
Technicals
50-Day MA
12.0493
200-Day MA
11.0219
52 Week High
15.5
52 Week Low
7.3
About KALV
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs.
Employees
150
Headquarters
Cambridge, MA
CEO
Mr. Benjamin L. Palleiko
Latest News
Top Gainers
Symbol/Name
LTP
% Chg
Top Losers
Symbol/Name
LTP
% Chg